740-Y-P-DataSheet-MedChemExpress

鱼酚氧化酶(PO)酶联免疫分析(ELISA)试剂盒使用说明书本试剂仅供研究使用目的：本试剂盒用于测定鱼血清，血浆，及相关液体样本中酚氧化酶(PO)的含量。

实验原理：本试剂盒应用双抗体夹心法测定标本中鱼酚氧化酶(PO)水平。

用纯化的鱼酚氧化酶(PO)抗体包被微孔板，制成固相抗体，往包被单抗的微孔中依次加入酚氧化酶(PO)再与HRP标记的酚氧化酶(PO)抗体结合，形成抗体-抗原-酶标抗体复合物，经过彻底洗涤后加底物TMB 显色。

TMB在HRP酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。

颜色的深浅和样品中的酚氧化酶(PO)呈正相关。

用酶标仪在450nm波长下测定吸光度（OD值），通过标准曲线计算样品中鱼酚氧化酶(PO)浓度。

试剂盒组成：试剂盒组成48孔配置96孔配置保存说明书1份1份封板膜2片（48）2片（96）密封袋1个1个酶标包被板1×481×962-8℃保存标准品：900pg/ml0.5ml×1瓶0.5ml×1瓶2-8℃保存标准品稀释液 1.5ml×1瓶 1.5ml×1瓶2-8℃保存酶标试剂3ml×1瓶6ml×1瓶2-8℃保存样品稀释液3ml×1瓶6ml×1瓶2-8℃保存显色剂A液3ml×1瓶6ml×1瓶2-8℃保存显色剂B液3ml×1瓶6ml×1瓶2-8℃保存终止液3ml×1瓶6ml×1瓶2-8℃保存浓缩洗涤液（20ml×20倍）×1瓶（20ml×30倍）×1瓶2-8℃保存样本处理及要求：1.血清：室温血液自然凝固10-20分钟，离心20分钟左右（2000-3000转/分）。

仔细收集上清，保存过程中如出现沉淀，应再次离心。

2.血浆：应根据标本的要求选择EDTA或柠檬酸钠作为抗凝剂，混合10-20分钟后，离心20分钟左右（2000-3000转/分）。

Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:YM155 (Sepantronium bromide) is a novel small molecule survivin suppressant with an IC50 of 0.54 nM for the inhibition of survivin promoter activity.IC50 Value: 0.54 nMTarget: SurvivinIn vitro: YM155 is not sensitive to survivn gene promoter–driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC–3 and PPC–1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c–IAP2, XIAP, Bcl–2, Bcl–xL, Bad,α–actin, and β–tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC–3 and PPC–1 with a concomitant increase in caspase–3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC–3, PPC–1, DU145, TSU–Pr1, 22Rv1, SK–MEL–5 and A375 with IC50 from 2.3 to 11 nM, respectively [1]. YM155 increases thesensitivity of NSCLC cells to γ–radiation. The combination of YM155 and γ–radiation increases both the number of apoptotic cells and the activity of caspase–3. YM155 delays the repair of radiation–induced double–strand breaks in nuclear DNA [2].In vivo: YM155 completely inhibits the tumor growth of PC–3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue.Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC–3 orthotopic xenografts [1]. The combination therapy with YM155 and γ–radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice [2].PROTOCOL (Extracted from published papers and Only for reference)Enzyme assay [1]:The caspase–3 activity was measured with a CPP32/Caspase–3 Fluometric Protease Assay Kit (MBL) according to the manufacturer's instructions. After incubation with YM155 for 48 h, PC–3 and PPC–1 cells were lysed in 100 μL of a cell lysis buffer (provided with the kit) and equal volumes (50 μL) of cell lysate were obtained (100 μg of protein). After addition of 2× reaction buffer, the mixture was added to a black 96–well plate. The DEVD–AFC substrate (appended with the kit) was then added at 5 mL/well and the mixture incubated at 37°C for 30 min. Fluorescence emissions were quantified with a spectrofluorometer at an excitation wavelength of 390nm and an emission wavelength of 460 nm.Cell assay(growth inhibition) [1]:The antiproliferative activity of YM155 was measured by the method used at the National Cancer Institute. After treatment with YM155for 48 h, the cell count was determined by sulforhodamine B assay. The GI50 value was calculated by logistic analysis, which is thedrug concentration resulting in a 50% reduction in the net protein increase (as measured by sulforhodamine B staining) in control cells during the drug incubation. The assay was done in triplicate, and the mean GI50 value was obtained from the results of fourProduct Name:YM–155Cat. No.:HY-10194CAS No.:781661-94-7Molecular Formula:C 20H 19BrN 4O 3Molecular Weight:443.29Target:Survivin; Autophagy Pathway:Apoptosis; Autophagy Solubility:DMSO: 10.66 mg/mLindependent assays.Animal administration [1]:Five–week–old male nude mice (BALB/c nu/nu) were purchased from Charles River Japan, Inc. PC–3 cells (2 × 106–3 × 106) were injected into the flanks of the mice and allowed to reach a tumor volume of >100 mm3 in tumor volume (length × width2 × 0.5). YM155 was s.c. administered as a 3–day continuous infusion per week for 2 weeks using an implanted micro–osmotic pump (Alzet model 1003D, Durect) or i.v. administered five times a week for 2 weeks. The percentage of tumor growth inhibition 14 days after initial YM155 administration was calculated for each group using the following formula: MTV = 100 × {1–[(MTV of the treated group on day 14)–(MTV of the treated group on day 0)] / [(MTV of the control group on day 14)–(MTV of the control group on day 0)]}, where MTV is mean tumor volume. For both the frozen tumors and plasma samples, survivin expression levels were analyzed by Western blotting and YM155 drug concentration by high–performance liquid chromatography/triple quadrupole mass spectrometry (LC/MS/MS) using validated methods.References:[1]. Nakahara T, et al. YM155, a novel small–molecule survivin suppressant, induces regression of established human hormone–refractory prostate tumor xenografts. Cancer Res. 2007 Sep 1;67(17):8014–21.[2]. Iisa T, et al. Radiosensitizing effect of YM155, a novel small–molecule survivin suppressant, in non–small cell lung cancer cell lines. Clin Cancer Res. 2008 Oct 15;14(20):6496–504.[3]. Guo K, et al. A combination of YM–155, a small molecule survivin inhibitor, and IL–2 potently suppresses renal cell carcinoma in murine model. Oncotarget. 2015 Aug 28;6(25):21137–47.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

美国贝克曼库尔特流式细胞分析仪（Beckman coulter cell）产品型号：Cell Lab Quanta SC当前价格：0.00元产品数量：0新旧程度：全新有效期至：0000-00-00所在地：产品简介：仪器简介：T细胞亚群检测的CD45/CD4/CD8/CD3、CD45/CD56/CD19/CD3；阵发性血红蛋白尿（PNH）检测的CD55、CD59；血小板无力症（GT）检测的CD41、CD61等等详细信息仪器简介：T细胞亚群检测的CD45/CD4/CD8/CD3、CD45/CD56/CD19/CD3；阵发性血红蛋白尿（PNH）检测的CD55、CD59；血小板无力症（GT）检测的CD41、CD61等等。

但对于白血病/淋巴瘤免疫分型，国际上迄今为止也没有统一的抗体组合。

在2000年国际细胞分析学会（ISAC）大会上，临床血细胞计数协会组织了一次国际专家会议，以期对检测血液淋巴系统肿瘤所需最少、最有效的单抗数达成共识。

75%与会者一致认为，对于慢性淋巴系统增殖性疾病（CLD）有9种单抗：CD5,CD19,κ,λ,CD3,CD20,CD23,CD10,CD45对初诊来说是最基本的。

淋巴瘤和CLD相似，需要至少12-16种单抗。

对于急性白血病（AL），75%的与会者认为大约13-15种单抗是最基本的：CD10,CD19,CD79a,CD13,CD33,CD34,CD45,CD2,MPO，CD7,CD14,CD3,HLA-DR等，对初步鉴别白血病系列是必需的。

其他一些（CD16,CD56,CDw65,TdT,cyCD3）可能对某些病例有用。

几乎所有的投票者都认为，要对急性白血病完善分类所需单抗的恰当数量平均为20-24种。

但这些抗体之间组合也是一大难题，目前也无统一规定（如表二）。

大会多数发言者(11/13)指出，对已确诊病人的监护和分期来说，仅需较少单抗。

抗体的质量控制是实验的关键环节。

抗体的质量包括其特异性、灵敏度、精密度。

manual Quick Taq HS Dye Mix 1306 F1138K Quick Taq HS DyeMixDTM-101 100 reactionsStore at -20°C Contents[1] Introduction[2] Components[3] Primer design[4] Analysis and Cloning of PCR products[5] Protocol1. Standard reaction setup2. Cycling conditions[6] Examples[7] TroubleshootingCAUTIONAll reagents in this kit are intended for research purposes. Do not use for diagnosis or clinical purposes. Please observe general laboratory precaution and utilize safety while using this kit.JAPAN CHINATOYOBO CO., LTD. TOYOBO Bio-Technology, CO., LTD.Tel(81)-6-6348-3888 Tel(86)-21-58794900.4140www.toyobo.co.jp/e/bio1JAPAN CHINA TOYOBO CO., LTD. TOYOBO Bio-Technology, CO., LTD.Tel(81)-6-6348-3888 Tel(86)-21-58794900.4140 www.toyobo.co.jp/bio/********************[ 1 ] Introduction[ 2 ] Components[ 3 ] Primer Design[ 4 ] Analysis andCloning of PCR productsDescriptionQuick Taq HS DyeMix is a Taq-based 2× master mix PCR reagent that contains anelectrophoresis dye (BPB; bromophenol blue) and anti-Taq antibodies for hot start PCR. This reagent contains all components for PCR except primers and template DNA. This reagent shows specific and efficient amplification. The amplified products can be directly loaded in the wells of agarose or acrylamide gels.Features-As this reagent contains bromophenol blue (BPB) as an electrophoresis dye; the PCR products can be analyzed directly with an agarose or acrylamide gel.-This reagent exhibits greater PCR performance than conventional rTaq DNA polymerase.-This reagent contains anti-Taq antibodies for hot start PCR. Hot start technology realizes highly specific and sensitive PCR.-This reagent is stable for at least three months at 4°C. No decrease in reaction efficiency is observed following 30 freeze-thaw cycles.-This reagent is suitable for a colony-direct PCR (see [6], Example 2).This reagent includes the following components for 100 reactions, 50 μl total reaction volume:2× Quick Taq HS DyeMix1.25ml× 2*In the case of the long-term storage (>3 months), this reagent should be stored at-20°C.Primers should be 22–35 bases long, with a melting temperature (Tm) > 60°C.-As this reagent contains bromophenol blue (BPB) as an electrophoresis dye and by adjusting its relative density, the PCR products can be applied directly to an agarose or acrylamide gel.-The PCR products can be cloned using general TA cloning technology.-The PCR products can be used as templates for sequencing after an appropriate treatment.JAPAN CHINA TOYOBO CO., LTD. TOYOBO Bio-Technology, CO., LTD.Tel(81)-6-6348-3888 Tel(86)-21-58794900.4140 www.toyobo.co.jp/bio/********************[ 5 ] Protocol[ 6 ] Examples1. Standard reactionBefore preparing the reaction mixture, the master mix solution should be completely thawed. *For the PCR reaction, thin-wall tubes are recommended. A total reaction volume of 50 μl is also recommended.2. PCR cycle conditionsExample 1. Amplification of the human p53 gene (2.9 kb)The human p53 gene (2.9 kb) was amplified using 50 ng of human genomic DNA.Quick Taq HS DyeMix successfully amplified the targets.Reaction volume 50 μl 20 μl Final concentrationAutoclaved, distilled water X μl X μl 2x Quick Taq HS DyeMix 25 μl 10 μl 1 × 10 pmol /μl Primer #1 1.0 μl 0.4 μl 0.2 μM 10 pmol /μl Primer #2 1.0 μl 0.4 μl 0.2 μM Template DNAY μlY μlGenomic DNA -200 ng / 50 μl Plasmid DNA -50 ng / 50 μl E. coli colonyTotal 50 μl 20 μl3-step cyclePredenaturation: 94°C , 2min. Denaturation: 94°C , 30sec. °C , 30sec. Extension: 68°C , 1min. /kb 2-step cyclePredenaturation: 94°C , 2min. Denaturation: 94°C , 30sec. Extension: 68°C , 1min. /kbJAPAN CHINA TOYOBO CO., LTD. TOYOBO Bio-Technology, CO., LTD.Tel(81)-6-6348-3888 Tel(86)-21-58794900.4140 www.toyobo.co.jp/bio/********************[ 7 ] Trouble shootingExample 2. Insert amplification by a colony-direct PCRThe inserts were amplified using Quick Taq HS DyeMix with universal primers from E. coli DH5α colonies bearing pTA2 plasmid (insert size: 500 bp). Quick Taq HS DyeMix successfully and efficiently amplified all targets.SymptomCauseSolutionNo PCR product / low yieldCycling conditions are not suitable.Increase the number of cycles by 2-5 cycles. Primer is not good.Check the quality of the primers. Redesign the primers.Template DNA is ofinsufficient quality and/or quantity.Check the quality of the template DNA. Increase the amount of the template DNA Too much sample Excessive amounts of bacterial cells may inhibit amplification. Decrease the sample volume. Smearing / Extra bandCycling conditions are not suitable.Decrease the number of cycles by 2-5 cycles.Primer concentration is not appropriate Optimize the primer concentration to around 0.1-0.2 μM.Annealing temperature is too low. Optimize the annealing temperature to around 55°C -65°C . Primer is not good. Check the quality of the primers. Redesign the primers. Too much template DNA Reduce the amount of template DNA。

Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:740 Y–P (PDGFR 740Y–P) is a potent and cell permeable PI3K activator.IC50 & Target: PI3K [1]In Vitro: 740 Y–P is a synthetic biotinylated peptide consisting of the 16–amino acid sequence derived from the third helix of the Antennapedia protein in tandem with a 9 amino acid phosphopeptide mimetic of the high affinity p85 binding site on the PDGFreceptor. 740 Y–P readily binds GST fusion proteins containing both the N– and C– terminal SH2 domains of p85. 740 Y–P fails to bind GST alone, or a GST fusion protein containing the N– terminal SH2 domain of PLCg and shows relatively weak binding of a GST fusion proteins containing the SH2 domain of Grb2. The 740 Y–P peptide is also able to specifically interact with p85 in cell lysates as shown by affinity precipitation. 740 Y–P stimulates mitogenesis at the lowest concentration tested (1 mg/mL). The peptide stimulates mitogenesis in both the presence and absence of serum (0.5%), and in the former instance a maximal response observed at 50mg/mL. 740Y–P peptide to stimulate mitogenesis is highly specific and not a general feature of a cell permeable SH2 domain binding peptides [1]. 740 Y–P potently inhibits the PI3K pathway. It remarkably reduces the number of M6PR–positive vacuoles induced by the sucrose treatment [2].In Vivo: 740 Y–P is not only internalised in living cells but can also interact with p85 in vivo .[1]PROTOCOL (Extracted from published papers and Only for reference)Cell Assay:[1]Following serum starvation, C2 cells are cultured in the presence of the PDGFR 740Y–P peptide at the givenconcentrations (0, 1, 10, 100 μg/mL) for 48 h. The mitogenic response is assessed by measurement of the percentage of cells in S–phase [1].References:[1]. Derossi D, et al. Stimulation of mitogenesis by a cell–permeable PI 3–kinase binding peptide.[2]. Bin BH, et al. Hyperosmotic stress reduces melanin production by altering melanosome formation. PLoS One. 2014 Aug 29;9(8):e105965.Product Name:740 Y–P Cat. No.:HY-P0175CAS No.:1236188-16-1Molecular Formula:C141H222N43O39PS3Molecular Weight:3270.70Target:PI3K Pathway:PI3K/Akt/mTOR Solubility:H 2OCaution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@ Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Jan.-15-2018Print Date:Jan.-15-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :740 Y-PCatalog No. :HY-P0175CAS No. :1236188-16-11.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Acute toxicity, Oral (Category 4),H302Acute aquatic toxicity (Category 1),H400Chronic aquatic toxicity (Category 1),H4102.2 GHS Label elements, including precautionary statementsPictogramSignal word No data availableHazard statement(s)H302 Harmful if swallowed.H410 Very toxic to aquatic life with long lasting effects.Precautionary statement(s)P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.P273 Avoid release to the environment.P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor ⁄ physician if you feel unwell.P330 Rinse mouth.P391 Collect spillage.P501 Dispose of contents ⁄ container to an approved waste disposal plant.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:740YPDGFR; PDGFR 740Y–PFormula:C141H222N43O39PS3Molecular Weight:3270.70CAS No. :1236188-16-14. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-80°C 2 years-20°C 1 yearIn solvent-80°C 6 months-20°C 1 month7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGUN number: 3077Class: 9Packing group: IIIEMS-No: F-A, S-FProper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.Marine pollutant: Marine pollutantIATAUN number: 3077Class: 9Packing group: IIIProper shipping name: Environmentally hazardous substance, solid, n.o.s.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

REF 10213-4 4 x 24mL总蛋白 (TP)楔形瓶，每瓶含试剂可用量 24mL。

预期用途EasyRA® TP 试剂目的是用于通过 MEDICA EasyRA 临床化学分析仪进行人血清或血浆（采用肝素锂作为抗凝血剂）中总蛋白的定量测定。

仅用于体外诊断用途。

仅供专业人员使用。

摘要和说明1, 2, 3在人血清中，血清蛋白主要包括白蛋白（占总蛋白的50-60%），其余部分包括α1-、α2-、β- 和γ-球蛋白。

总蛋白的浓度对维持血液和组织之间水的正常平衡与交换是很重要的。

血清蛋白浓度较低，可能是由于吸收不良、合成受损引起的，或是由于出血或过度分解代谢导致蛋白损失而引起的，如肾病和肝病中观察到的情况，这种情况可能导致低蛋白血症。

在高免疫球蛋白血症（如多发性骨髓瘤和感染）或脱水情况下，可能发生高蛋白血症。

方法的原理本分析法采用双缩脲反应测定血清蛋白，其中碱性溶液中的二价铜离子与化合物（含 2 个或多个、与碳原子结合的酰胺基或肽基）反应，形成一种有色络合物4。

碱性 pH血清蛋白质类 + Cu++———— 紫色络合物紫色络合物以分光光度法在 550nm 处测定，以 700nm 作为空白波长。

在较宽的线性范围内，该络合物的密度与蛋白质浓度成正比5。

试剂五水合硫酸铜0.3g/dL氢氧化钠0.8g/dL碘化钾、酒石酸钾钠和叠氮化钠作为防腐剂。

注意事项1.当处理任何实验室试剂时，应遵守良好实验室安全规范(CLSI, GP17-A2)。

2.氢氧化钠具有腐蚀性，能引起烧伤。

不要用嘴吸取试剂。

如果吞服，应立即就医处理。

避免眼部和皮肤接触。

如发生眼部接触，立即用大量水清洗眼睛，并就医处理。

如果发生皮肤接触，用水清洗皮肤至少 15 分钟。

3.本试剂含叠氮化钠 <0.1%；叠氮化钠可与铅和铜水管反应，形成高爆炸性金属叠氮化物。

请参考化学品安全说明书中的危险、危害和安全信息。

4.就任何诊断试验方法而言，其结果应根据所有其它试验结果和患者的临床状况加以解释。

北京春达科技有限公司专营进⼝体外诊断试剂⼯业原料，透析产品，纯化填料，标准品SCLPP209碱性磷酸酶3.1.3.1Alkaline phosphatase from Calf intestine-Activity: >30000 U/mlGlycerol solution-Mw: 100,000-Store at -20 °CSCMAD211苹果酸脱氢酶1.1.1.37Malate dehydrogenase from Microorganism-Activity: >40 U/mgYellowish amorphous powder-Mw: 140,000-Store at -20 °CSCMDH18C苹果酸脱氢酶1.1.1.37Malate dehydrogenase from Pig heart-Activity: >1250 U/mgprot.White amorphous powder-Mw:140,000-Store at -20 °CSCMDL100苹果酸脱氢酶1.1.1.37Malate dehydrogenase from Microorganism-Activity: >60 U/mgWhite amorphous powder-Mw: 80,000-Store at -20 °CSCMUT11C变旋酶5.1.3.3Mutarotase from Porcine kidney-Activity: >1500 U/mgWhite amorphous powder-Mw: 40,000-Store at -20 °CSCMUT12C变旋酶5.1.3.3Mutarotase from Porcine kidney-Activity: >1000 U/mlAmmonium sulfate suspension-Mw: 40,000-Store at 2-8 °CSCNAL301唾液酸醛缩酶4.1.3.3N-Acetylneuraminic acid aldolase from MicroorganismActivity: >15 U/mg-Yellowish amorphous powderMw: 98,000-Store at -20 °CSCPCO301原⼉茶酸3,4双加氧酶1.13.11.3Protocatechuate 3,4-dioxygenase from Pseudomonas sp.Activity: >3 U/mg-Light brown amorphous powderMw: 700,000-Store at -20 °CSCPEO131过氧化物酶1.11.1.7Peroxidase from Horseradish, Grade IActivity: >250 U/mg-Reddish-brown amorphous powderMw: 40,000-Store at -20 °CSCPEO301过氧化物酶1.11.1.7Peroxidase from Horseradish, Grade I-Activity: >250 U/mgReddish-brown amorphous powder-Mw: 40,000-Store at -20°CSCPEO302过氧化物酶1.11.1.7Peroxidase from Horseradish, Grade III-Activity: >110 U/mgReddish-brown amorphous powder-Mw: 40,000-Store at -20°CSCPHO12C磷脂酶D Phospholipase D from Streptomyces chromofuscus3.1.4.4Activity: >40 U/mg-Brown amorphous powderMw: 57,000-Store at -20 °CSCPNP301嘌呤核苷磷酸化酶2.4.2.1Purine-nucleoside phosphorylase from MicroorganismActivity: >15 U/mg-White amorphous powderMw: 120,000-Store at -20 °CSCPPC301磷酸烯醇式丙酮酸羧化酶4.1.1.31Phosphoenolpyruvate carboxylase from Corn leavesActivity: >5 U/mg-White amorphous powderMw: 390,000-Store at -20 °CSCPSP101脯氨酸特定的肽链内切酶3.4.21.26Proline specific endopeptidase from Flavobacterium sp.Activity: >5 U/mg-White amorphous powder-Mw: 78,000-Store at -20 °CSCPYK302L丙酮酸激酶2.7.1.40Pyruvate kinase from Rabbit muscle-Activity:＞2000 U/mlwhite ammonium sulphate suspension-Mw:237000-Store at 2-8℃SCPYO311丙酮酸氧化酶1.2.3.3Pyruvate oxidase from Microorganism-Activity: >1.5 U/mgYellowish amorphous powder-Mw: 260,000-Store at -20 °CSCSAO341肌氨酸氧化酶1.5.3.1Sarcosine oxidase from Microorganism-Activity: >8 U/mgYellowish amorphous powder-Mw: 65,000-Store at -20 °CSCSAO351肌氨酸氧化酶1.5.3.1Sarcosine oxidase from Microorganism-Activity: >8 U/mgYellowish amorphous powder-Mw: 43,000-Store at -20 °CSCSOD302超氧化物歧化酶1.15.1.1Superoxide dismutase from Bovine erythrocyte-Activity: >3000U/mgBluish-green amorphous powder-Mw: 32,000-Store at -20 °CSCUAO201尿酸酶1.7.3.3Uricase from Candida sp.-Activity: >4 U/mg-White amorphous powder-Mw: 120,000-Store at -20 °CSCUAO211尿酸酶1.7.3.3Uricase from Bacillus sp.-Activity:>1.5 U/mg-White amorphous powder-Mw: 150,000-Store at -20 °CSCURH10S脲酶3.5.1.5Urease from Jack bean-Activity: >220 U/mg-White amorphous powder-Mw: 480,000-Store at -20 °CSCURH16C脲素酶GUrease G from Jack bean-Activity: >150 U/mgWhite amorphous powder-Mw: 480,000-Store at -20 °C3.5.1.5SCURH201脲素酶Urease from Jack bean-Activity: >100 U/mgWhite amorphous powder-Mw: 480,000-Store at -20 °C3.5.1.5SCXTO212黄嘌呤氧化酶Xanthine oxidase from Microorganism-Activity: >10 U/mgReddish-brown amorphous powder-Mw: 160,000-Store at -20°C1.1.3.222.诊断与研究⽤的辅酶CODES PRODUCTS CAS #SCADP01C 腺苷5'-⼆磷酸单钾盐⼆⽔合物ADP-K.2H2O-Adenosine 5’-diphosphate monopotasium saltdihydrate-C10H14N5O10P2K.2H2O-Mw:501.30-Colorless crystals-Purity:>95 %72696-48-1SCADP22C 腺苷5’-⼆磷酸⼆钠盐ADP-Na2-Adenosine 5’-diphosphate disodium salt-C10H13N5O10P2Na2-Mw:471.20-White powder-Purity:>98 %16178-48-6SCAMP02C 腺苷-5’-磷酸AMP-Adenosine 5’-monophosphoric acid-C10H14N5O7P.H2O-Mw:365.20-White powder-Purity:>98 %18422-05-4SCAMP05C 腺苷5’-磷酸AMP-Na2-Adenosine 5’-monophosphate disodium salt -C10H12N5O7PNa2-Mw:391.18-White powder-Purity:>95%18422-05-4SCATP03C 腺苷5’-三磷酸⼆钠盐3⽔合物ATP-Na2.3H2O-Adenosine 5’-triphosphate disodium salttrihydrate -C10H14N5Na2O13P3.3H2O -Mw:605.19-White powder-Purity:>96 %987-65-5SCBNA207C β-烟酰胺-腺嘌呤⼆核苷酸NAD-β-Nicotinamide-adenine dinucleotide-C21H27N7O14P2-Mw:663.4-White powder-Purity:>98 %53-84-9SCBND210C β-烟酰胺腺嘌呤⼆核苷磷酸，还原型四钠盐NADPH-Na4-β-Nicotinamide-adenine dinucleotide phosphate, reducedtetrasodium salt-C21H26N7O17P3.Na4-Mw:833.40-White powder-Purity:>93 %2646-71-1SCBNH208C β-烟酰胺腺嘌呤⼆核苷酸，还原⼆钠盐NADH-Na2-β-Nicotinamide-adenine dinucleotide, reduceddisodium salt -C21H27N7P2O14Na2-Mw:709.40-White to yellowish powder-Purity:>93 %606-68-8β-烟酰胺腺嘌呤⼆核苷酸磷酸⼆钠盐24292-60-2SCBNP209C β-烟酰胺腺嘌呤⼆核苷酸磷酸⼆钠盐NADP-Na2-β-Nicotinamide-adenine dinucleotide phosphatedisodium salt-C21H26N7O17P3Na2-Mw:787.40-Yellowishpowder-Purity:>97 %24292-60-2SCCOA11C 辅酶A三锂盐Coenzyme A trilithium salt-C21H33Li3N16O7P3S-Mw:785.40-White powder-Purity:>85 %18439-24-2SCDAD631C ⼆(腺苷-5’-)五磷酸三锂盐Ap5A-Li3-P1,P5 –Di(adenosine -5’-)pentaphosphate trilithiumsalt-C20H26N10O22P5Li3-Mw:934.20-Yellowish powder-Purity:>95 %75522-97-3SCFAD11C 黄素腺嘌呤⼆核苷酸⼆钠盐FAD- Na2-Flavine-adenine dinucleotide disodium salt-C27H31N9O15P2Na2-Mw:829.60-Orange powder-Purity:>93 %146-14-5SCNAL24C N-⼄酰-L-半胱氨酸N-Acetyl-L-cysteine-C5H9NO3S-Mw:163.20-White powder-Purity:>98 %616-91-1SASNAD 硫代辅酶IThio-NAD-C21H27N7O13SP2-Purity:≥ 90%4090-29-3SASNADP 硫代辅酶IIThio-NADP-C21H27N7O16P3S•Na- Purity:≥ 90%19254-05-8SAAldNAD 3-吡啶⼄醛腺嘌呤⼆核苷酸3-Pyridinealdehyde adenine dinucleotide C21H27N6O14P21986-7-7SAAC1023-⼄酰基吡啶腺嘌呤⼆核苷酸磷酸钠(Ac-NADP) APADP-C22H28N6O17P3•Na -Purity:≥ 80%102029-67-4SANAAD 烟酸腺嘌呤⼆核苷酸Nicotinic Acid Adenine Dinucleotide- C21H26N6O15P2104809-30-5SADeNAD 脱氨基NADDeamino Nicotinamide Adenine Dinucleotide-C21H26N6O15P2104809-38-3SAGGNAFB γ-L-⾕氨酰基-4-硝基苯胺Gamma-L-glutamyl-4-nitroanilide,-C11H13N3O5-Purity:≥ 96%7300-59-6SACGGN L-γ-⾕氨酸-(3-甲酸-4硝基苯胺)铵盐L-Glutamic Acid Gamma- (3-Carboxy-4-Nitroanilide),Ammonium Salt-C12H12N3O7P•NH4-Purity:≥ 96%63699-78-5SAPEPCHA 磷酸烯醇丙酮酸单环⼰胺盐PEP-C3H4O6P•C6H13N-Purity :＞95%10526-80-4SAPEPK 磷酸烯醇式丙酮酸单钾盐PEP-C3H4O6P•K-Purity :＞95%4265-07-03.诊断与研究⽤的底物CODES PRODUCTS CAS #SCAKE05C α–酮戊⼆酸⼆钠盐⼆⽔合物α–Ketoglutaric acid, disodium salt dihydrate-C5H4O5Na2.2H2O-Mw:226.10 -White powder-Purity:>98%305-72-6α–酮戊⼆游离酸328-50-7SCAKE115C α–酮戊⼆游离酸α–Ketoglutaric free acid-C5H4O5-Mw:146.10 -White powder-Purity:>99%328-50-7SCBTC06S-丁酰硫胆碱碘S-Butyrylthiocholine Iodide-C9H20NOSI-Mw:317.23 -White powder-Purity:>97%1866-16-6SCCNP005Gal-G2-α-CNP-C28H51O18Cl-Mw:659.98 -White powder-Purity:>90 %157381-11-8SCCRP59C 磷酸肌酸⼆钠盐四⽔合物Phosphocreatine disodium salt tetrahydrate-C4H8N3O5PNa2.4H2O-Mw:327.15 -White powder-Purity:>97 %19333-65-4SCGGC106C ⽢氨酰⽢氨酸Glycylglycine-C4H8N2O3-Mw:132.12-White powder-Purity:>98 %556-50-3SCGLT100L-⾕氨酸L-Glutamic acid-C5H9N2O4- Mw:147.13-White powder-purity:＞99%617-65-2SCGPS15C 葡萄糖-6-磷酸⼆钠盐Glucose-6-phosphate disodium salt-C6H11O9PNa2-Mw:304.20-White powder-Purity:>95 %3671-99-6SCLAC171C DL-乳酸锂盐DL-Lactic acid Lithium salt-C3H5O3Li-Mw:96.01-White powder-Purity:>95%16891-53-5SCLAL29C L-丙氨酸游离酸L-Alanine free acid-C3H7NO2-Mw:89.09-White powder-Purity:>99%56-41-7SCLAP41C L-天门冬氨酸L-Aspartic acid-C4H7NO4-Mw:133.10-White powder-Purity:>99 %56-84-8SCLAP42C L-天门冬氨酸,钠盐⼀⽔合物L-Aspartic acid, sodium salt monohydrate-C4H6NO4Na.H2O-Mw:173.10-White powder-Purity:>98 %323194-76-9SCLAP43C L-天门冬氨酸,镁⼆⽔合物L-Aspartic acid, magnesium salt dihydrate-C8H12N2O8Mg.2H2O-MW:324.50-White powder-Purity:>98 %2068-80-6SCLGC244C L-γ-⾕氨酰-3-羧基-4-硝基苯胺Glupa C-L-γ-Glutamyl-3-carboxy-4-nitranilide-C12H12N3O7NH4-Mw:328.30-Yellow powder-Purity:>99 %63699-78-5SCNAY138C 萘磷酸单钠盐Naphtyl phosphate, monosodium salt-C10H8NaO4P.H2O-Mw:264.15-White powder-Purity:>98%81012-89-7SCPG701C 亚⼄基降-4-硝基苯基-β-D-麦芽庚糖苷pNP-G7-Ethylidene-4-nitrophenyl-D-maltoheptaoside-C50H77NO38-Mw:1300.10-Yellowish powder-Purity:>90%96597-16-9对硝基苯基磷酸酯，⼆钠盐六⽔合物4264-83-9SCPNP264C 对硝基苯基磷酸酯，⼆钠盐六⽔合物PNPP-p-Nitrophenylphosphate, disodium salt hexahydrate-C6H4NO6PNa2.6H2O-Mw :371.10-White to yellow powder-Purity:>98%4264-83-9SCPNS265C p-硝基苯基磷酸酯，⼆tris盐PNPP diTris-p-Nitrophenylphosphate, ditris salt-C14H28N3O12P-Mw:461.40-White powder68189-42-4SCPYN100丙酮酸钠Sodium pyruvate-C3H3NaO3-Mw:110-White powder-Purity:>99%113-24-64.缓冲液Buffers for diagnostic & researchPRODUCTS CAS # N-(2-⼄酰胺基)-2-氨基⼄磺酸ACES-N-(2-Acetamido)-2-aminoethanesulfonic acid7365-82-4N-(2-⼄酰胺基)亚氨基⼆⼄酸ADA-(N-(2-Acetamido)iminodiacetic acid)26239-55-4 2-氨基-2-甲基-1-丙醇AMT -2-amino-2-methyl-1-propanol124-68-5 N,N-双(2-羟⼄基)-2-氨基⼄磺酸BES-N,N-Bis-(2-Hydroxyethyl)-2-Aminoethanesulfonic acid10191-18-1 N,N-双-(2-羟基⼄基)⽢氨酸Bicine-N,N-Bis-(2-Hydroxyethyl)glycine150-25-4 N-环⼰基-3-氨基丙磺酸CAPS-N-Cyclohexyl-3-aminopropanesulfonicacid1135-40-6N-环⼰基-2-羟基-3-氨基丙磺酸CAPSO -N-Cyclohexyl-2-hydroxy-3-aminopropanesulfonic acid73463-39-5。

ASTAspartate Aminotransferase IFCCMANUAL RX MONZAINTENDED USEFor the quantitative in vitro determination of AspartateAminotransferase (AST) in serum and plasma. This product is suitable for manual use and on the Rx Monza analyser.Cat. No. AS 1202 R1a. Buffer/Substrate 1 x 70 ml 20 x 2 ml R1b. Enzyme/Coenzyme/ 20 x 2 ml α-oxoglutarate GTIN: 05055273200416AS 1204 R1a. Buffer/Substrate 1 x 105 ml 10 x 10 ml R1b. Enzyme/Coenzyme/ 10 x 10 ml α-oxoglutarate GTIN: 05055273200423AS 1267 R1a. Buffer/Substrate 1 x 105 ml 5 x 20 ml R1b. Enzyme/Coenzyme/ 5 x 20 ml α-oxoglutarate GTIN: 05055273200430AS 2359 R1a. Buffer/Substrate 5 x 100 ml 5 x 100 ml R1b. Enzyme/Coenzyme/ 5 x 100 ml α-oxoglutarate GTIN: 05055273200454UV METHODThis is an optimised standard method according to the concentrations recommended by the IFCC.CLINICAL SIGNIFICANCE (1,2,3,4)The aminotransferases are a group of enzymes that catalyse the inter conversions of amino acids and α-oxoacids by transfer of amino groups. AST (aspartate aminotransferase or glutamate oxaloacetatetransaminase) has been found in the cytoplasm and the mitochondria of cells that have been studied. In cases of mild tissue damage, e.g. liver, the predominant form of serum AST is that from the cytoplasm, with a smaller amount coming from the mitochondria. Severe tissue damage will result in more mitochondrial enzyme being released. Elevated levels of AST can signal myocardial infarction, hepatic disease, muscular dystrophy and organ damage.Although heart muscle is found to have the most activity of the enzyme, significant activity has also been seen in the brain, liver, gastric mucosa, adipose tissue and kidneys of humans.The IFCC has now recommended (1980) standardised procedures for AST determinations including:-1. optimization of substrate concentrations.2. Employment of Tris buffers (instead of phosphate, which has beenshown to inhibit recombination of the apoenzyme with pyridoxal phosphate).3. Pre-incubation of combined buffer and serum to allow sidereactions with NADH to occur. 4. Substrate start (α-oxoglutarate)5. Optional pyridoxal phosphate activation.This is an optimised standard method according to the recommendations of the IFCC.PRINCIPLEα-oxoglutarate reacts with L-aspartate in the presence of AST to form L-glutamate plus oxaloacetate. The indicator reaction utilises the oxaloacetate for a kinetic determination of NADH consumption. AST -oxoglutarate + L-aspartate L-glutamate + oxaloacetate MDH oxaloacetate + NADH + H + L-malate + NAD +SPECIMEN COLLECTION AND PREPARATION (5) Serum:- Use serum free from haemolysis.Plasma:- EDTA or heparin can be used as the anticoagulant.Plasma should be separated from cells within one hour after collection.Specimens should be refrigerated if not used immediately:-Specimens stored longer than 3 days should be frozen at -20︒C.REAGENT COMPOSITIONContents Concentrations in the TestR1a. Buffer/Substrate Tris buffer 80 mmol/l, pH 7.5 L-aspartate 240 mmol/l R1b. Enzyme/Coenzyme/α-oxoglutarate α-oxoglutarate 12 mmol/l MDH ≥420 U/l LD ≥600 U/l NADH 0.18 mmol/lSAFETY PRECAUTIONS AND WARNINGS For in vitro diagnostic use only. Do not pipette by mouth.Exercise the normal precautions required for handling laboratory reagents.Solution R1a contains Sodium Azide. Avoid ingestion or contact with skin or mucous membranes. In case of skin contact, flush affected area with copious amounts of water. In case of contact with eyes or if ingested, seek immediate medical attention.Sodium Azide reacts with lead and copper plumbing, to form potentially explosive azides. When disposing of such reagents flush with large volumes of water to prevent azide build up. Exposed metal surfaces should be cleaned with 10% sodium hydroxide.Health and Safety data sheets available on request.The reagents must be used only for the purpose intended by suitably qualified laboratory personnel, under appropriate laboratory conditions.STABILITY AND PREPARATION OF REAGENTS R1a. Buffer/SubstrateContents ready for use. Stable up to the expiry date when stored at +2 to +8︒C.R1b. Enzyme/Coenzyme/α-oxoglutarate Reconstitute one vial of Enzyme/Coenzyme/α-oxoglutarate R1b with the appropriate volume of Buffer/Substrate R1a: 2 ml for the 20 x 2 ml kit (AS 1202) 10 ml for the 10 x 10 ml kit (AS 1204) 20 ml for the 5 x 20 ml kit (AS 1267) Stable for 14 days at +2 to +8︒C or 24 hours at +15 to +25︒C. Cat. AS 2359 5 x 100 mlReconstitute one vial of Enzyme/Coenzyme/α-oxoglutarate R1b with a portion of Buffer/Substrate R1a and then transfer the entire contents to bottle R1a rinsing bottle R1b several times. Stable for 14 days at +2 to +8︒C or 24 hours at +15 to +25︒C.MATERIALS PROVIDED Buffer/SubstrateEnzyme/Coenzyme/ -oxoglutarateMATERIALS REQUIRED BUT NOT PROVIDEDRandox Assayed Multisera Level 2 (Cat. No. HN 1530) and Level 3 (Cat. No. HE 1532)Randox Calibration Serum Level 3 (Cat. No. CAL 2351) RX series Saline (Cat. No. SA 3854)PROCEDUREAspirate fresh ddH 2O and perform a new Gain Calibration in flow cell mode. Select AST in the Run Test screen and carry out a water blank as instructed.Pipette into a test tube:Sample 0.05 ml Reagent 0.5 mlMix and aspirate into the Rx Monza.CALIBRATION FOR RX MONZAThe use of Saline and Randox Calibration Serum Level 3 isrecommended for calibration. Calibration is recommended with change of reagent lot or as indicated by quality control procedures.FOR MANUAL USEWavelength: 340 nm (Hg 334 nm or Hg 365 nm) Cuvette: 1 cm light path Temperature: 25/30/37︒C Measurement: against airPipette into cuvette: Macro MicroSample 0.2 ml 0.1 ml Enzyme/Coenzyme/ α-oxoglutarate R1 2.0 ml 1.0 mlMix, read initial absorbance after 1 minute. Read again after 1, 2 and 3 minutes. Note: If the absorbance change per minute is between 0.11 and 0.16 at 340/Hg 334 nm 0.06 and 0.08 at Hg 365 nmuse only the values for the first 2 minutes for the calculation.MANUAL CALCULATIONTo calculate the AST activity, use the following formulae:U/l = 1746 x A 340 nm/min U/l = 1780 x A Hg 334 nm/min U/l = 3235 x A Hg 365 nm/minSTANDARDISATIONRandox Calibration Serum Level 3 is traceable to AST reference material JSCC TS01.QUALITY CONTROLRandox Assayed Multisera, Level 2 and Level 3 are recommended for daily quality control. Two levels of controls should be assayed at least once a day. Values obtained should fall within a specified range. If these values fall outside the range and repetition excludes error the following steps should be taken:1. Check instrument settings and light source.2. Check cleanliness of all equipment in use.3. Check water. Contaminants, i.e. bacterial growth, maycontribute to inaccurate results. 4. Check reaction temperature.5. Check expiry date of kit and contents.6. Contact Randox Laboratories Customer Technical Services, Northern Ireland +44 (0) 28 9445 1070.SPECIFICITY/INTERFERENCE (6,7)Gross haemolysis will produce falsely elevated test results. The effects of various drugs on AST activity should be taken intoconsideration in the case of patients receiving large doses of drugs.The analytes below were tested up to the following levels and were found not to interfere: Haemoglobin 250 mg/dl Free Bilirubin 25 mg/dl Conjugate Bilirubin 25 mg/dl Triglycerides 1000 mg/dlIntralipid ® 200 mg/dlA list of substances and conditions known to effect AST activity in vivo is given by both Young et al and Friedman et al. Norepresentation is made by Randox Laboratories Ltd regarding the completeness of these lists and the accuracy of the information contained therein.NORMAL VALUES IN SERUM (8,9) +25︒C +30︒C +37︒C Men up to 18 U/l up to 25 U/l up to 37 U/l Women up to 15 U/l up to 21 U/l up to 31 U/lIt is recommended that each laboratory establish its own reference range to reflect the age, sex, diet and geographical location of the population.SPECIFIC PERFORMANCE CHARACTERISTICS The following performance data were obtained using an Rx Monza analyser running at +37o C.LINEARITYThis method is linear up to 562 U/l. If the sample concentration exceeds this value, dilute the sample 1+9 with 0.9% NaCl solution and re-assay. Multiply the result by 10.SENSITIVITYThe minimum detectable concentration of AST with an acceptable level of precision was determined as 9.3 U/l.PRECISIONIntra AssayLevel 2 Level 3Mean (U/l) 35.6 153SD 1.66 1.47CV(%) 4.65 0.96n 20 20Inter AssayLevel 2 Level 3Mean (U/l) 35.6 153SD 1.77 7.10CV(%) 4.96 4.63n 20 20CORRELATIONThis method (Y) was compared with another commerciallyavailable method (X) and the following linear regression equationobtained:Y = 1.07X + 4.9and a correlation coefficient of r = 0.997543 patient samples were analysed spanning the range 28 to 559U/l.REFERENCES1. Wroblewski F, La Due J.S: Ann Intern Med. 1956; 45: 801.2. Wroblewski F, La Due J.S: Proc Soc Exp Biol Med 1956;91: 569.3. Bergmeyer HU, Bowers GN Jr, et al: Clin Chem 1977; 23:887.4. Bergmeyer HU, Bowers GN Jr, et al: J.Clin Chem ClinBiochem 1980; 18: 521-534.5. Tietz N W: Fundamentals of Clinical Chemistry ed 3.Philadelphia, WB Saunders Co. 1987, pg 372.6. Young D S, et al: Clin Chem 1975, 21; No5.7. Friedman RB, et al: Clin Chem 1980, 26; No4.8. Wallnofer H, Schmidt.E, Schmidt FW, eds: Synopsis derLeberkrankheiten Stuttgart, Georg Thieme Verlag, 1974.9. Thefeld W, et al: Dtsch Med Wschr 1974; 99: 343.Revised 26 Apr 16 biRev. 003THIS PAGE IS INTENTIONALLY BLANK。

Expression, Purification and Crystallization of the Mycobacterium Tuberculosis HSP16.3 Molecular Chaperone Background of Mycobacterium Tuberculosis HSP16.3HSP16.3, a 16.3 kDa protein from Mycobacterium Tuberculosis, was originally identified as a prominent antigen (Kingston et al., 1987). During the stationary phase, HSP16.3 is maximally expressed and becomes a main protein of the latent phase (Yuan et al., 1996). Previous studies showed that HSP16.3 can make the cell structure stable and prevent stationary Mycobacterium Tuberculosis from autolysing (Cunningham et al., 1998). In previous studies, HSP16.3 was found as one of theα-crystallin-related small heat shock proteins (sHSP) with molecular chaperone activity. Experiments in vitro revealed that HSP16.3 can suppress the thermal aggregation of citrate synthase at 39.5˚C, without consumption of A TP (Chang et al., 1996).Now the Mycobacterium Tuberculosis HSP16.3 gene was cloned to the plasmid pSTE-HSP16.3, and transformed to E.Coli. BL21(DE3) strain.Material and MethodExpressionThings to have ready before Starting.-Plate or glycerol culture-Sterile LB 25ml in a 50mL shaker flasker, 250ml in a 500mL shaker flasker, all together autoclaved, antibiotic added afterword.- antibiotic and sterile water- TipsPrepare the LB and autoclave:Fomula of the LB medium for 1 Liter:Bacto Tryptone (BT) 10 gBacto Y east Extract (BYE) 10 gNaCl 10gThe LB medium, dd H2O and the tips all together autoclaved at 121 ˚C for 20 minutes.Method:1 Innoculate 25 ml LB Medium ( containing 100 ug) and grow culture overnight(37˚C, 200rpm).2 Next morning inoculate 250 ml prewarmed LB Medium ( containing 100 ug) with the 25 ml overnight culture and grow at 37 ˚C, 200rpm, HSP16.3 was overexpressed in soluble form intracellularly without IPTG induction.3 Incubate the Culture for 10 hours before havesting the cell at 4000 g for 20 minutes.4 Resuspend the cell pellet in 30 ml Butter A and freeze the Sample in -80˚C refigerator.PurificationDE52 Ion-Exchange columnThings to have ready before Starting.-Butter A: 50 mM Imidazole pH 6.5 (1 liter)-Butter B: 50 mM Imidazole pH 6.5 , 300mM NaClall together Fitrate with 0.2 um membrane.- DE52 medium , column ,Gradient maker, UV-monitor and Fractioner- TipsMethod:1 Thaw the cell pellet and vortex .2 Add 0.4ml 100 mM PMSF and sonicate (400kw, 4s-6s 50 cycle* 5 )3 Centrifuge 15000 rpm, 30 minutes to pellet debris4 Transfer supernatant to a 50 ml conicale tube and discard the pellet.5 The supernatant dilute to 50 ml with Buffer A and then load to DE52 ion-exchange columns (20ml), which was pre-equibrated with 100ml Buffer A. And then wash the unbound proteins with 100 ml Buffer A.6 Elute the protein with a linear gradient : 200ml buffer A plus 200ml buffer B, 2ml/min, 6ml each fraction.7 Run 15% SDS-PAGE to determine the HSP16.3 peak.Desalting by dialysis1 Preparation of the dialysis tubeCut the tube in a suitable length (20-30 cm)Boil the tube in solution containing 10 mM NaHCO3 for a few minutes.Boil the tube in solution containing 10 mM EDTA for a few minutes.Rasin the tube with de-ion water2 Pool the HSP16.3 peak and dialysis the Sample against 1000ml Buffer A for more than 6hours.Q-Separose (HP) Ion-Exchange Column1 load the sample to Q-Separose (HP) Ion-Exchange column (20ml), which was pre-equibrated with 100ml Buffer A. And then wash the unbound proteins with 100 ml Buffer A.2 Elute the protein with a linear gradient : 200ml buffer A plus 200ml buffer B, 2ml/min, 6ml each fraction.3 Run 15% SDS-PAGE to determine the purity of the HSP16.3 peak.Gel filtration ColumnThe HSP peak was a final volumn 0.3ml and then run though a Superdex75 (HR, 10/30mm) gel filtration column in 150mM NaCl and 5mM Imdazole, pH6.5. Crystallization1 The purified HSP16.3 was solvent-exchanged to water and concentrated to 20mg/ml before crystallization trails (Bradford). All the crystallization trials were carried out using the hanging-drop vapor-diffusion method at 291K: drops consisted of2 microlitres of HSP16.3 protein solution plus 2 microlitres of the precipitant. The drops were equilibrated against 0.2 ml precipitant at room temperature. The crystallization conditions were investigated with a PEG4000 Kit.Result and discussionThe purity of the final HSP16.3 was over 95% by SDS-PAGE. The crystallization trials of HSP16.3 yielded Cubic crystals with a size of 0.8*0.8*0.6mm in a few days.20040060080010001200mAUBuffer Tris-HCL pH 8.5 Precipitant PEG 4000 MethodV apor Diffusion Temperature 293 K Size0.8*0.8*0.6mmReferencesChang Z., Primm, T.P., Jakana J., Lee H. I., Serysheva I., Chiu W., Gilber H. F., Quiocho F. A., (1996) J Biol Chem 271:7218-7223Cunningham A. F., Spreadbury C. L., (1998) J. Bacteriol. 184:801-808Kingston A. E., Salgame P. R., Mitchison N.A., Colston M. J. (1987) Infect. Immun 55,3149-3154Yuan Y., Crane D. D., Barry C. E. III (1996) J Bacteriol178: 4484-4492。

碧云天生物技术/Beyotime Biotechnology 订货热线：400-1683301或800-8283301 订货e-mail ：******************技术咨询：*****************网址：碧云天网站 微信公众号EDTA 抗原修复液(50X)产品编号 产品名称包装 P0085EDTA 抗原修复液(50X)100ml产品简介：碧云天生产的EDTA 抗原修复液(EDTA Antigen Retrieval Solution)是一种常用的抗原修复液，可以用于石蜡切片、冰冻切片等样品使用多聚甲醛、甲醛或其它醛类试剂固定后的抗原修复。

细胞或组织用多聚甲醛、甲醛或其它醛类试剂固定后，会导致蛋白之间的交联(cross-link)，从而遮蔽样品的抗原位点，导致免疫染色时染色信号减弱，甚至出现一些假阳性染色结果。

本抗原修复液采用了广泛使用的EDTA ，可以有效去除醛类固定试剂导致的蛋白之间的交联，充分暴露石蜡切片等样品中的抗原表位，从而大大改善免疫染色效果。

通常石蜡切片都需进行抗原修复处理，而冰冻切片可以不进行抗原修复处理。

抗原修复会大大改善石蜡切片的免疫染色效果，但对于冰冻切片的染色效果很多文献资料表明也有显著改善。

特别是当冰冻切片免疫染色效果欠佳时，可以考虑尝试进行抗原修复。

从原理上来看，无论冰冻切片还是细胞爬片等，只要是用多聚甲醛、甲醛或其它醛类试剂固定的样品，进行抗原修复都会有效去除蛋白之间的交联，充分暴露抗原表位，从而大大改善免疫染色效果。

本产品特别适合用于石蜡切片，也可以用于冰冻切片等其它样品。

关于碧云天生产的各种抗原修复液的主要特点和差异可参考我们的相关网页：/support/antigen-retrieval-solution.htm 。

一个包装的本产品可以配制成5000毫升抗原修复液(1X)。

按照每个片子需要10毫升抗原修复液(1X)计算，一个包装的本产品可以用于500个样品。

BL21-CodonPlus-RP Competent Cells, Part Number 230250*************(24小时)化学品安全技术说明书GHS product identifier 应急咨询电话（带值班时间）::供应商/ 制造商:安捷伦科技贸易（上海）有限公司中国（上海）外高桥自由贸易试验区英伦路412号（邮编:200131)电话号码： 800-820-3278传真号码: 0086 (21) 5048 2818BL21-CodonPlus-RP Competent Cells, Part Number 230250化学品的推荐用途和限制用途BL21-CodonPlus-RP competent cells 230250-41pUC 18 DNA Control Plasmid 200231-42XL10-Gold 2-Mercaptoethanol 200314-43部件号:物质用途:分析试剂。

230250-41BL21-CodonPlus-RP competent cells1 ml（毫升） (10 x 100 µl)200231-42pUC 18 DNA ControlPlasmid0.01 ml（毫升） (0.1 ng/µl)200314-43XL10-Gold2-Mercaptoethanol0.05 ml（毫升）部件号（化学品试剂盒）:230250安全技术说明书根据 GB/ T 16483-2008 和 GB/ T 17519-2013GHS化学品标识:BL21-CodonPlus-RP 感受态细胞，部件号 230250物质或混合物的分类根据 GB13690-2009 和 GB30000-2013紧急情况概述BL21-CodonPlus-RP competent cells液体。

pUC 18 DNA Control Plasmid 液体。

Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:Alda–1 is a potent ALDH2 agonist, which significantly improves ALDH2 activity.In Vivo: Alda–1 treatment results in a significant decrease of 4–HNE–protein content in the plasma of apoE -/- mice. Alda–1administration leads to a slight increase in gene expression related to neurogenesis (Nog ), mitochondrial biogenesis (CYTB , ND1),and apoptosis (Bax , Gsk3b ) in the Hp of apoE -/- mice. Alda–1 administration leads to 2 and 10 differentially expressed proteins in theFCx and Hp of apoE -/- mice, respectively [1]. Alda–1 (1.5 mg/kg, b.w., i.p.) administration significantly increases the climbing time,tends to reduce the immobility time and increases the swimming time of the prenatally stressed rats in the forced swim test.Moreover, treatment of prenatally stressed rats with Alda–1 significantly increases number of entries into the open arms of the maze and the time spent therein, as assessed by elevated plus–maze test [2]. Alda–1 (8.5 mg/kg, i.p.) with glucose significantly lowers 4–HNE and FJB–positive cells in the cerebral cortex of Alda–1–treated rats than in DMSO–treated rats 24 h after glucose administration [3]. Alda–1 (10 mg/kg per day) treatment prevents aldehydic overload, mitochondrial dysfunction and improves ventricular function in post–MI cardiomyopathy rats [4].PROTOCOL (Extracted from published papers and Only for reference)Cell Assay:[2]Spleen cells (4×106 cells/mL) are stimulated by optimal concentrations of concanavalin A (Con A; 2.5μg/mL and 0.6 μg/mL) and lipopolysaccharide (LPS, 5 μg/mL) and are incubated in 96–well plates at final volume of 0.2mL for 72 h. Cell proliferation is determined by adding 0.5 μCi of [3H]–thymidine per well at 16 h before the end of the incubation.The cultures are harvested with an automatic cell harvester, and [3H] thymidine incorporation is assessed using a liquid scintillationcounter.Animal Administration: Alda–1 is dissolved in 1 mL/kg b.w. DMSO/water 50/50.[2]After behavioral verification at three months of age,the animals are divided into the following four groups: control, control + Alda–1, prenatally stressed and prenatally stressed + Alda–1(6 animals per group). Alda–1 injections are given intraperitoneally (i.p.) once daily at a dose of 1.5 mg/kg b.w. (dissolved in 1 mL/kg b.w. DMSO/water 50/50) for 14 days. At the same time, the control and prenatally stressed rats receive 1 mL/kg b.w. DMSO/water 50/50. The injections of Alda–1 and vehicle are given between 10 a.m and 11 a.m. In the last five days of Alda–1 treatment the behavioral parameters in the elevated plus maze test and then in the forced swim test are measured.References:[1]. Stachowicz A, et al. Proteomic Analysis of Mitochondria–Enriched Fraction Isolated from the Frontal Cortex and Hippocampus of Apolipoprotein E Knockout Mice Treated with Alda–1, an Activator of Mitochondrial Aldehyde Dehydrogenase (ALDH2). Int J Mol Sci.[2]. Stachowicz A, et al. The impact of mitochondrial aldehyde dehydrogenase (ALDH2) activation by Alda–1 on the behavioral and biochemical disturbances in animal model of depression. Brain Behav Immun. 2016 Jan;51:144–53.Product Name:Alda–1Cat. No.:HY-18936CAS No.:349438-38-6Molecular Formula:C 15H 11Cl 2NO 3Molecular Weight:324.16Target:Aldehyde Dehydrogenase (ALDH)Pathway:Metabolic Enzyme/Protease Solubility:DMSO: ≥ 51 mg/mL[3]. Ikeda T, et al. Effects of Alda–1, an Aldehyde Dehydrogenase–2 Agonist, on Hypoglycemic Neuronal Death. PLoS One. 2015 Jun 17;10(6):e0128844.[4]. Gomes KM, et al. Aldehydic load and aldehyde dehydrogenase 2 profile during the progression of post–myocardial infarction cardiomyopathy: benefits of Alda–1. Int J Cardiol. 2015 Jan 20;179:129–138.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

细胞总抗氧化能力（TAC）比色法（DPPH）定量检测试剂盒产品说明书（中文版）主要用途细胞总抗氧化能力（TAC）比色法（DPPH）定量检测试剂盒是一种旨在通过有机氮自由基染料DPPH的参与，在抗氧化剂的存在下，通过分光光度仪，观察其峰值下降的变化，来定量检测对应于标准水溶性生育酚Trolox的总抗氧化能力，即消除自由基等值浓度的权威而经典的技术方法。

该技术经过精心研制、成功实验证明的。

适用于各种新鲜食物样品总抗氧化能力检测。

产品严格无菌，即到即用，操作简易，性能稳定。

技术背景超氧自由基阴离子（superoxide radical；O2-）、过氧化氢（hydrogen peroxide；H2O2）、羟自由基或氢氧基（hydroxyl radical；OH-）、过氧化基（peroxyl radical；ROO-）、氢过氧自由基（hydroperoxyl；HOO）、烷氧自由基（alcoxyl radical）、氮氧基（nitric Oxide；NO-）、过氧亚硝基阴离子（peroxynitrite anion；ONOO-）次氯酸（hypochlorous acid；HOCl）、半醌自由基（semiquinone radical）、单线态氧气（singlet oxygen）等细胞内活性氧族（Reactive Oxygen Species；ROS）的产生和增多，将导致细胞衰老或凋亡，甚而导致诸如冠心病、风湿性关节炎、肿瘤、退行性病变等各种病理状况。

在生物系统内，通过抗氧化酶例如超氧化物歧化酶、过氧化氢酶和谷胱甘肽过氧化物酶等，大分子，例如白蛋白、铜蓝蛋白（ceruloplasmin；CER）、铁蛋白（ferritin）和抗氧化因子，例如生育醇、类胡萝卜素、抗坏血酸、还原性谷胱甘肽和尿酸胆红素（bilirubin）等，产生抗氧化能力，即捕获自由基的能力，达到消除或降低ROS的损害。

通过稳定的有机氮自由基染料1,1-二苯基-2-三硝基苯肼（1,1-Diphenyl-2-picrylhydrazylradical；DPPH），受到抗氧化剂的去自由基作用，呈现深紫色转化为黄色的变化，衡量体系中抗氧化剂捕获自由基、消耗抗氧化剂的能力，在分光光度仪（515nm波长）的帮助下，观察其峰值下降的变化，并与标准化抗氧化剂水溶性生育酚Trolox对照。